Cancer treatment reviews
-
Cisplatin-based treatment has significantly increased survival in testicular cancer patients. Therefore, there has been enough interest for the late toxic effects of chemotherapy which affect the quality of life of the cancer survivors. ⋯ Physicians should also be aware of the risk of secondary malignancy development. Therefore, close follow-up of the testicular cancer survivors as well as, focus on minimizing treatment complications through improvement of treatment strategies are warranted.
-
Cancer treatment reviews · May 2010
ReviewManagement of treatment-related adverse events in patients with multiple myeloma.
The introduction of novel antimyeloma therapies, including thalidomide, lenalidomide and bortezomib, has expanded treatment options for patients with multiple myeloma. These compounds alter the natural history of multiple myeloma and help improve outcomes, but have different and specific toxicity profiles. ⋯ Herein we evaluate the incidence of treatment-related adverse events associated with each of these compounds. We further review the management of these adverse events with a view to delivering optimal therapeutic outcomes in patients with newly diagnosed and relapsed and/or refractory multiple myeloma.
-
In the last decade, advances in our understanding of the biology of myeloma have led to new treatment approaches that have resulted in unprecedented improvements in survival outcomes. These gains can be attributed in part to the introduction of three new active agents for the treatment of myeloma: thalidomide, lenalidomide, and bortezomib. With these treatments, however, have come new questions regarding the optimal approach to therapy, expected outcomes, and safety issues. In the articles included in this supplement, experts at the forefront of myeloma research provide insight into the management of patients with myeloma, and the current issues that clinicians face today regarding the best use of these agents.